XML 66 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Quarterly Financial Information (Unaudited) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
Revenues:                      
License and milestone fees $ 305 $ 305 $ 25,678 $ 13,167 $ 855 $ 22,010 $ 429 $ 933 $ 39,455 $ 24,227 $ 9,161
Royalty revenue 3,400 2,558 2,335 2,053 592       10,346 592  
Research and development support 1,327 1,948 1,922 1,990 2,203 2,257 2,036 1,377 7,187 7,873 4,517
Clinical materials revenue 711 2,064 125 8 181 734 147 1,781 2,908 2,843 2,679
Total revenues 5,743 6,875 30,060 17,218 3,831 25,001 2,612 4,091 59,896 35,535 16,357
Operating Expenses:                      
Research and development 25,787 38,280 20,862 22,029 20,399 21,318 21,656 23,700 106,958 87,073 69,192
General and administrative 6,456 6,040 5,447 6,526 5,373 4,995 5,464 5,639 24,469 21,471 20,422
Total operating expenses 32,243 44,320 26,309 28,555 25,772 26,313 27,120 29,339 131,427 108,544 89,614
Loss from operations (26,500) (37,445) 3,751 (11,337) (21,941) (1,312) (24,508) (25,248) (71,531) (73,009) (73,257)
Other income (expense), net 1 (7) 62 111 66 (39) 115 56      
Net loss $ (26,499) $ (37,452) $ 3,813 $ (11,226) $ (21,875) $ (1,351) $ (24,393) $ (25,192) $ (71,364) $ (72,811) $ (73,319)
Basic and diluted net loss per common share (in dollars per share) $ (0.31) $ (0.44) $ 0.04 $ (0.13) $ (0.26) $ (0.02) $ (0.29) $ (0.30) $ (0.83) $ (0.87) $ (0.95)